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Abstract
Pseudomonas aeruginosa is a Gram-negative bacterium known to cause opportunistic
infections in immune-compromised or immunosuppressed individuals that often prove fatal.
New drugs to combat this organism are therefore sought after. To this end, we subjected
the gene products of predicted perturbative genes to structure-based druggability predic-
tions using DrugPred. Making this approach suitable for large-scale predictions required the
introduction of new methods for calculation of descriptors, development of a workflow to
identify suitable pockets in homologous proteins and establishment of criteria to obtain valid
druggability predictions based on homologs. We were able to identify 29 perturbative pro-
teins of P. aeruginosa that may contain druggable pockets, including some of them with no
or no drug-like inhibitors deposited in ChEMBL. These proteins form promising novel targets
for drug discovery against P. aeruginosa.
Introduction
Attrition rates in the drug discovery process are high. Studies have revealed that 80% of drug
discovery projects fail to produce clinical candidates and only 2% actually produce marketed
drugs. Poor target selection was found to be a major factor for the failures [1]. Hence, target
selection is an important consideration for drug discovery. The advent of large-scale genomics
projects has introduced a plethora of plausible targets. Target selection has traditionally been
guided by biological or technical aspects such as assay feasibility. However, high-throughput
screening against targets where chemical tractability has not been established may lead to unsa-
tisfying hit rates [2]. This raises the need for low-cost methodologies to assist with target selec-
tion. Recently, computational methods have been introduced for this purpose. One option is to
prioritize targets based on homology with other targets already possessing high-affinity ligands
[3–7]. Alternatively, one can assess the binding sites of potential targets to estimate their suit-
ability as drug targets.
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Targets likely to bind orally bioavailable drugs with high affinity possess binding sites that
complement the nature of these molecules These binding sites are commonly referred to as
being druggable [8]. This distinguishes them from other binding sites which are referred to as
“less-druggable” or “non-druggable”. The probability of deriving a drug-like ligand with high
binding affinity for a protein possessing a “druggable” pocket is therefore higher than for oth-
ers. The term “druggability” itself is hotly debated and several alternative terms such as “bind-
ability”, “ligandability”, “tractability” or “chemical tractability” have been proposed. We will
use the term “druggability” throughout this manuscript because it is the prevalent term used in
literature.
Over the last few years, several methods have been reported that are able to segregate drug-
gable pockets from less-druggable ones [9–20]. DrugPred is one such druggability prediction
method [21]. DrugPred describes the size and shape of the binding site using a “superligand”,
which is obtained by merging predicted binding modes of drug molecules that were docked
into the pocket using only steric constraints. Descriptors encoding polarity and size of the
pocket are subsequently calculated based on the superligand and used to predict the druggabil-
ity of the binding site. We had previously found DrugPred to perform uniformly on the
NRDLD dataset containing proteins with druggable and less druggable binding sites as well as
other datasets, with ~90% prediction accuracy, which was superior to other methods we had
tested [21]. Desaphy et al. found that our linear model was approximately as accurate as their
Support Vector Machine-based method, both of which were better than two other methods
[11]. Even though the variability in metrics used to determine robustness of druggability pre-
diction methods makes it difficult to meaningfully compare and contrast them, it is clear that
DrugPred is one of the more accurate and reliable methods reported thus far [8,11]. Here, we
test the use of this method in identifying druggable proteins on a genome-wide scale. For this
study, we chose Pseudomonas aeruginosa as a model organism.
P. aeruginosa is a Gram-gram negative bacterium that has proven to be difficult to treat
with antibiotics. It often causes opportunistic infections in hospitalized patients of cystic fibro-
sis [22] and burn victim who are immunosuppressed or immunocompromised [23]. Chemo-
therapeutic intervention is therefore required, which is made difficult when infection is caused
by resistant strains of bacteria. Studies with transposon mutant libraries have identified pertur-
bative proteins in P. aeruginosa, i.e. proteins that are either essential, potentially essential or
else virulence factors [24,25]. A comprehensive database of P. aeruginosa genes and related
information is available in the AEROPATH database (aeropath.lifesci.dundee.ac.uk), including
essentiality labels as described by the above studies [24,25]. There are 5677 genes reported in
the AEROPATH database, of which 992 are predicted to be perturbative. Crystal structures are
available in the public domain (RCSB Protein Data Bank) for 77 of the perturbative gene prod-
ucts. Crystal structures are also available for homologs of 565 of the remaining perturbative
proteins.
Structures of perturbative genes in the AEROPATH database were analysed using DrugPred
in order to evaluate the use of such methods for genome-wide druggability predictions and to
prioritize proteins for drug discovery. While it was straightforward to assess pockets of avail-
able crystal structures of P. aeruginosa proteins, the real challenge was to make predictions for
pockets in proteins where no solved structure was available. To this end, we established a work
flow for homology-based druggability assessment. We also compared the predictions to che-
mogenomics-based predictions and discuss similarities between the two systems, along with
the advantage of using both systems simultaneously in order to prioritize targets. Finally, we
suggest potential new drug targets for P. aeruginosa.
Druggability Predictions for Pseudomonas aeruginosa Proteins
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Results
Constructing DrugPred 2.0
Analysis of protein druggability on a large scale required the use of a high-throughput drugg-
ability prediction algorithm. In order to scale up the original DrugPred’s performance, we re-
engineered the method for smooth execution on a compute cluster and introduced some
changes in the descriptor calculation methodology. Previously, the relative polar surface area
(psa_r), total hydrophobic surface area (hsa_t) and total contact surface area (csa) of a binding
site were calculated using the MOLCAD module in SYBYL-X (Tripos, St. Louis, Missouri,
USA) [21]. In the current version, these descriptors were calculated with Openeye’s OEChem
TK and Spicoli TK (OpenEye Scientific Software, Santa Fe, NM) [26,27]. This decision was
made due to license restrictions and easier integration in the Python code. All other descriptors
were calculated as reported previously [21]. Retraining and revalidation of the original
DrugPred statistical models was carried out to identify any changes in performance. The
NRDLD dataset of 115 structures was modified as per previous recommendations [21]. Thia-
mine purophosphokinase (TPK) was eliminated because there are no clinically used drugs for
this target, apart from thiamine, which is actually a substrate, making it unclear if TPK is drug-
gable. Urokinase Plasminogen activator (uPA) and human thymidine phosphorylase (HTP)
were eliminated, because all known modulators are either highly charged or else require
administration as prodrugs, against the very definition of druggability [21]. The binding sites
of hydroxynitrile lyase (HNL) and angiotensin-converting enzyme 1 (ACE-1) vary significantly
from other members of the dataset, making them unsuitable for model development [21].
Thereafter, the new dataset containing 110 proteins was divided into a training set of 75 struc-
tures and a validation set of 35 structures (Table A in S1 File). Descriptors were calculated for
the training set and a new Partial Least Squares-Discriminant Analysis (PLS-DA) model was
built as done previously [21]. The new model, which we named DrugPred 2.0, was used to
obtain scores for all training and test set structures, following which accuracy, precision and
recall values were calculated as done previously [21]. Briefly, accuracy describes the success
rate of categorizing pockets as druggable or less-druggable, precision describes the rate of cor-
rect calls by the model (e.g. how many data points predicted to be druggable were truly drug-
gable), and recall describes the ability of the model to correctly identify members of a category
(e.g., how many of the druggable proteins were correctly categorized). Comparing the two
models, we found that all three statistical values were similar for both models. In our original
report, we had also employed an ambiguous zone. This is a region of scores where it is difficult
to identify targets as belonging to either the druggable or less-druggable categories [21]. When
applying such a zone with DrugPred 2.0, similar results were obtained (Table 1). For the sake
Table 1. Accuracy, recall and precision values for training and validation sets for DrugPred 1 and 2.0.
DrugPred
version
Data set With/ without ambiguous
zone
Accuracy Recall (Druggable/ Less
druggable)
Precision (Druggable/Less
druggable)
1 Ω Training Without 0.91 0.96/0.83 0.90/0.93
2.0 0.91 0.94/0.86 0.92/0.89
1 Ω With 0.92 0.95/0.86 0.91/0.93
2.0 0.95 0.98/0.9 0.95/0.95
1 Ω Validation Without 0.89 0.91/0.85 0.91/0.85
2.0 0.94 0.95/0.93 0.95/0.93
1 Ω With 0.91 0.91/0.92 0.95/0.86
2.0 0.97 1.00/0.92 0.95/1.00
Ω Values taken from Krasowski et al [21]
doi:10.1371/journal.pone.0137279.t001
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of simplification, during the rest of this manuscript, we will highlight only those results where
an ambiguous zone was employed and any data points that lay within this zone were discarded
for calculation of final results.
Homolog-based druggability predictions
For the majority of essential or potentially essential proteins from P. aeruginosa in the AERO-
PATH database no crystal structure was deposited in the PDB. However, structures of homolo-
gous proteins were available for 565 of them. It is common practice to assume that homologs
of a target already known to be modulated by small molecules are druggable as well, particu-
larly if the sequence homology is high [3–7,17]. It was therefore interesting to test whether
DrugPred predictions could be transferred between homologous pockets as well. We also
wanted to establish a sequence identity cut-off at which such transfers could be made and a
minimum number of structures required for reliable transfers.
With this aim in mind, we embarked on a study to identify structural homologs of the modi-
fied NRDLD dataset and to score their pockets using DrugPred 2.0. The predictions were then
compared to the classification of the parent structures. Homologous structures were found for
all but three proteins in the dataset. For 19 proteins, none of the homologous structures con-
tained a ligand to mark the binding site and they were therefore not considered further. The
druggability of the homologous binding sites in the remaining 88 proteins was predicted. The
predictions for all homologs of six of these proteins were outside the model as judged by high
distance-to-model in X-plane (DModX) values. DModX represents the distance of a data point
from a hyperplane that represents the model. Smaller values demonstrate a higher likelihood
that data points are within the predictive domain of the model, while higher values demon-
strate that predictions for the data points may be unreliable. Predictions with a high DModX
value were therefore not analysed further. Thus, the final dataset consisted of 3186 homologous
pockets for 82 proteins. The total number of homologous pockets per dataset pocket ranged
from 1 to 208 and the sequence identity between the homologs and parent proteins from 22.3
to 89.9% (Table B in S1 File). The percentage of homologous pockets whose classification cor-
rectly reflected the druggability of the parent pocket ranged from 0% to 100% (Fig 1A). In the
majority of the cases the druggability prediction of the homologous pockets was correctly
transferable to the parent pocket, e.g. for 57 out of 82 proteins at least 90% of the homologous
pockets provided the correct prediction. Of these 57, 51 showed 100% correct predictions.
However, there were 12 instances where more than 50% of predictions for homologs did not
match the druggability of the dataset pocket. Therefore, we attempted to identify filter criteria
to obtain more reliable predictions.
It would be useful if we could establish (A) a sequence-cut off, (B) a requirement of mini-
mum number of homologs, and/or (C) a minimum percent consensus in predictions for
homologs, as suitable criteria to make the predictions more reliable. Hence, we first plotted the
percent homologs that reflected the parent structure’s druggability (% correct predictions) for
various bins of percent sequence identity to the parent structure (Fig 1B). There was no rela-
tionship between sequence identity of the homologous proteins and the percentage of correct
predictions observed. The same was observed when instead of the sequence identity only the
identity of the binding site residues was considered (Fig 1C). Similarly, percent correct predic-
tions did not increase with the number of homologs used for assessment (Fig 1D). We went on
to investigate if the parent protein pocket’s druggability could be predicted by a consensus
between its homologs. For this purpose, percent consensus between different homologous
pockets belonging to the same NRDLD parent entry was calculated using the formula: (100|
#druggable—#less-druggable|)/(total number of predictions). This measure enabled us to
Druggability Predictions for Pseudomonas aeruginosa Proteins
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Fig 1. The basis for homolog-based druggability predictions. (A) Homologous pockets whose classification correctly reflected the druggability of the
parent pocket. The data was binned according to percent correct predictions among the scored pockets for each parent homolog. The number of NRDLD
proteins that fitted into each category was then plotted (frequency and percentages are both shown). (B) Correct predictions in relationship to sequence
identity. The percent identity between NRDLD dataset structures and homologous chains was noted. The homologs were then binned according to their
percent sequence identity. The percent of homologs whose predictions matched that of the NRDLD dataset pocket was plotted for each bin. (C) Correct
predictions in relationship to sequence identity of binding site residues only. Plotted as described for (B), but instead of the sequence identity only the identity
of the binding site residues was used. (D) Percent correct predictions in relationship to number of assessed homologs. (E) Percent consensus in relationship
to percentage of correctly predicted NRDLD dataset pockets. The NRDLD dataset pockets were binned into two categories, where either <80% or80%
consensus (see methods) in druggability predictions for their respective homologs was observed. The percentage of NRDLD pockets whose druggability was
correctly reflected by consensus amongst their homologs was then plotted for each of these bins.
doi:10.1371/journal.pone.0137279.g001
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identify how many homologous pockets gave us the same prediction regardless of the predic-
tion itself. We then binned the NRDLD pockets into two categories, with either80% consen-
sus or<80% consensus amongst all homologs (Fig 1E). With<80% consensus in their
druggability prediction, only ~62% of the parent NRDLD pocket’s druggabilities was predicted
correctly. However, with at least 80% consensus, ~93% of the parent NRDLD pockets were cor-
rectly predicted. The latter value increased to 100%, when additionally at least 5 homologs
were assessed. Hence, we identified a dual-filter approach to obtain reliable homolog-based
druggability predictions using DrugPred 2.0. This formed the basis for the subsequent evalua-
tion of P aeruginosa proteins where no crystal structure has yet been solved.
Structure-based druggability analysis of P. aeruginosa proteins
Information for 5677 genes is stored in the AEROPATH database (Table 2). Of those, 992 are
annotated to be perturbative. Crystal structures for 77 of those gene products have been deter-
mined. Homologous structures for a further 565 perturbative gene products were available.
The available crystal structures were subjected to structure-based druggability predictions
using DrugPred 2.0.
The analysis of available Pseudomonas protein structures was straightforward. Pockets were
identified by bound ligands. Subsequently, the druggability was assessed using DrugPred 2.0
and pockets not fitting to the model were removed (as judged by DModX values). A gene prod-
uct was considered druggable if it possessed at least one pocket with a druggable score. Follow-
ing this procedure druggability scores could be obtained for 103 pockets from 34 Pseudomonas
proteins (out of 77 perturbative genes for which crystal structures were available, Table 2). Of
those 13 were found to possess pockets likely to bind drug-like molecules with high affinity
(Table 3).
The analysis of gene products lacking crystal structures, but where homologous structures
were available, was more convoluted. In the AEROPATH database crystal structures of homol-
ogous proteins are linked to P. aeruginosa gene products. However, there is no annotation if
these crystal structures cover the same sequence segment of the gene, which is particularly rele-
vant for multi-domain and multi-pocket proteins (Fig 2A). Therefore, it had to be ensured that
only corresponding pockets of the homologs were compared when assessing the druggability
of a parent protein. This was achieved using the following workflow (Fig 2B): First, DrugPred
2.0 was used to score all pockets marked by a ligand in the structures of homologous proteins
for a particular parent sequence. In the next step any pockets with high DModX values or
Table 2. Overview of triaging the genes stored in the AEROPATH database to enable structure-based
druggability predictions for P. aeruginosa proteins.
Number of
entities
1) Genes stored in AEROPATH database 5677
2) Annotated to be perturbative 992
3) Perturbative gene products originating from P. aeruginosa for which crystal
structures are available
77
3a) Proteins for which valid druggability predictions were obtained 24
3b) Proteins predicted to be druggable (Table 3) 13
4) Proteins encoded by perturbative genes for which crystal structures of homologous
proteins were available
565
4a) Proteins for which valid druggability predictions were obtained 241
4b) Proteins predicted to be druggable (Table 4) 16
doi:10.1371/journal.pone.0137279.t002
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scores within the ambiguous zone were discarded. Subsequently, the sequence of residues
forming each homologous pocket was determined. Next, the domains represented by this
sequence was determined by pairwise BLAST [28] searches with an E-value cut-off of 1e-5. For
each domain identified, the homologous structures were aligned and the number of pockets
represented was then determined by pairwise comparison of ligand positions. For final assess-
ment, only corresponding pockets represented in at least five different crystal structures were
retained. A protein pocket was considered to be druggable, if at least 80% consensus was
reached among the homologs and the majority of the pockets were predicted druggable. Fol-
lowing this workflow, starting from 565 gene products for which homologous structures were
available, valid (low DModX) predictions were obtained for 241 (Table 3). A total of 16 P. aeru-
ginosa gene products were found to possess pockets likely to bind drug-like ligands (Table 4).
Experimental support for DrugPred-based findings
It is already known that some proteins, out of those predicted to be druggable using DrugPred
2.0, are capable of strongly binding drug-like molecules; this is strong support for the predic-
tions. For example, UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC, Table 3) is a well-
Table 3. List of P. aeruginosa protein crystal structures containing pockets that are predicted to be druggable.
Pseudomonas gene
code
Product name Gene
name
PDB
code
Ligand Chemogenomics-based
druggability ranka
PA0019 Polypeptide deformylase def 1lry BB2 3 (2)
1ix1 BB2
PA0395 Twitching motility protein pilT 3jvv ACP -
PA1148 Exotoxin A precursor toxA 1aer AMP -
1dma AMP
NCA
1aer TIA
1xk9 P34
1zm9 P34
PA1430 Transcriptional regulator lasR 2uv0 OHN 8 (6)
3ix3 OHN
3ix4 TX1
3jpu TY4
3ix8 TX3
PA1900 Probable phenazine biosynthesis protein phzB2 3ff0 UNL -
PA2386 L-ornithine-N5-oxygenase pvdA 3s61 ORN -
PA3155 UDP-2-acetamido-2-dideoxy-D-ribohex-3-uluronic
acid transaminase
wbpE 3nyu LLP -
PA3540 GDP-mannose-6-dehydrogenase algD 1muu GDX -
1mv8 GDX
PA3724 Elastase lasB 3dbk RDF 4 (3)
PA4279 Hypothetical protein (probable pantothenate kinase) 2f9w PAU -
PA4406 UDP-3-O-acyl-N-acetylglucosamine deacetylase
(LpxC)
lpxC 2ves GVR 1
PA4407 Cell division protein ftsZ 1ofu GDP 115 (29)
PA5163 Glucose-1-phosphate thymidylyltransferase (RmlA) rmlA 1g3l TRH -
1fxo TMP
aRanks obtained when only perturbative proteins are considered are given in brackets.
doi:10.1371/journal.pone.0137279.t003
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studied target for antibacterial compounds and a number of drug-like ligands has been discov-
ered [29]. Similar, dihydrofolate reductase (DHFR, Table 4) is an established target for antibi-
otics which are routinely used in man [30]. Recently, drug-like inhibitors of
phosphopantetheine adenylyltransferase (PPAT) were discovered and their activity against a
range of bacterial strains was demonstrated [31]. An interesting case is also glucose-1-phos-
phate thymidylyltransferase (RmlA, Table 3). The crystal structure of RmlA was reported ear-
lier [32] (RCSB PDB code: 1fxo), with TMP bound at the active and allosteric sites. Both these
sites were assessed using DrugPred 2.0 and it was found that the allosteric site scored druggable
Fig 2. Complexity of homolog-based identification of pertinent pockets in proteins. A) A hypothetical
target protein is depicted with three homologous proteins. The target protein consists of two domains, one
shown in blue and the other in red. These domains may be represented by complete or partial sequences in
homologs. For example, homologs 1 and 2 possess short domains homologous to the target protein's blue
domain. On the other hand, homolog 3 possesses a sequence match for the red domain. Each target protein
domain possesses pockets (denoted by black, green, red and blue ovoids), which may or may not be
identified by the presence of ligands in homologs. Here, the black pocket is also represented in homolog 3,
but the green pocket is not. The red pocket is observed in both, homolog 1 and 2, but the blue pocket is only
represented in homolog 1. B) Workflow to identify druggable pockets in homologs proteins.
doi:10.1371/journal.pone.0137279.g002
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while the active site scored less druggable. Interestingly, a high-throughput screen, followed by
rational drug design resulted in nanomolar inhibitors of RmlA [33]. These inhibitors were
characterised crystallographically and it was observed that all these compounds bound at the
allosteric regulatory site that scored druggable.
Comparison with a chemogenomics-based druggability rankings
Bickerton et al. have introduced a chemogenomics-based druggability prediction method for P.
aeruginosa proteins, which is available through the AEROPATH database. This method utilizes
ChEMBL [34] data to identify compounds possessing high affinity or ligand efficiency for spe-
cific targets, which are further quantified by Quantitative Estimate of Druggability (QED) mea-
surements [35]. Proteins with a larger number of QED-positive compounds are judged to be
more druggable. Furthermore, homologs of druggable protein domains are also considered to
be druggable. The P. aeruginosa proteins were then ranked according to the scores obtained
(http://aeropath.lifesci.dundee.ac.uk/pages/background).
We compared DrugPred 2.0 predictions with this chemogenomics-based ranking system.
Predictions could be obtained for 158 perturbative gene products using the latter system, and
Table 4. List of P. aeruginosa proteins predicted to possess a druggable pocket.
PA
Code
Representative homolog
(PDB code / ligand)
# of
HAα
% Sequence
ID range
# of predictions druggable /
less druggable / ambiguous
Product Name Gene
Name
RankΩ
PA0350 2qk8 / MTX 11 39.76–48.78 11 / 0 / 0 Dihydrofolate reductase
(DHFR)
folA 85 (22)
PA0363 1b6t / COD 7 40.51–60.00 6 / 1 / 0 Phosphopante-theine
adenylyltrans-ferase (PPAT)
coaD -
PA1648 2dm6 / IMN 6 38.07–39.66 6 / 0 / 0 Probable oxidoreductase 685
(126)
PA1671 1ig1 / ANP 9 26.85–28.66 9 / 0 / 0 Serine-threonine kinase Stk1 Stk1 195
(42)
PA1778 1cbf / SAH 9 28.65–46.15 9 / 0 / 0 Uroporphyrin-III C-
methyltrans-ferase
cobA -
PA2086 1vj5 / CIU 7 29.82–29.82 7 / 0 / 0 Probable epoxide hydrolase 336
(62)
PA2344 1tz3 / AIS 6 25.10–30.35 5 / 0 / 1 Fructokinase mtlZ -
PA2965 1b3n / CER 9 39.49–66.50 9 / 0 / 0 Beta-ketoacyl carrier protein
synthase II
fabF1 119
(30)
PA2967 1doh / NID 8 34.23–37.70 7 / 0 / 1 3-oxoacyl-[acyl carrier
protein] reductase
fabG 80 (21)
PA3883 1a27 / EST 9 34.81–35.19 9 / 0 / 0 Probable short-chain
dehydrogenase
32 (11)
PA4068 1lrl / UPG 6 30.97–33.55 6 / 0 / 0 Probable epimerase 544
(98)
PA4385 1a6e / ADP 17 21.93–80.69 17 / 0 / 0 GroEL protein groEL -
PA4386 1aon / ADP 7 57.45–61.46 7 / 0 / 0 GroES protein groES -
PA4439 1i6k / TYM 11 31.66–33.73 9 / 0 / 2 Tryptophanyl-tRNA
synthetase
trpS -
PA5174 1b3n / CER 8 27.88–28.36 8 / 0 / 0 Probable beta-ketoacyl
synthase
488
(83)
PA5288 1v3s / ATP 12 41.07–77.68 10 / 1 / 1 Nitrogen regulatory protein
P-II 2
glnK -
α HA: distinct homologous pockets assessed
Ω Rank: Chemogenomics-based druggability rank. Ranks obtained when only perturbative proteins are considered are given in brackets.
doi:10.1371/journal.pone.0137279.t004
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for 265 gene products using DrugPred 2.0 (Table 2). There was an overlap of 38 gene products
using both methods, 17 of which were predicted to possess druggable pockets by DrugPred. A
good agreement was found between DrugPred 2.0 predictions and top scoring chemoge-
nomics-based predictions. All gene products for which crystal structures from P. aeruginosa
proteins were available and which ranked among the top 10 perturbative gene products using
the chemogenomics-based system were predicted to be druggable by DrugPred 2.0 (Table 3).
Some gene products that ranked low in the chemogenomics-based method were still classified
to be druggable by DrugPred 2.0 (Table 4).
Discussion
The DrugPred methodology was redevised for high-throughput operation, involving the intro-
duction of robust methods for calculation of descriptors. The new version of this druggability
prediction method showed accuracy, precision and recall parameters similar to the older ver-
sion (Table 1) and it is therefore suitable for large-scale predictions.
Criteria for homolog-based druggability predictions were established. Coverage of perturba-
tive P. aeruginosa gene products by crystal structures is low (Table 2). Crystal structures for
only 77 out of 992 perturbable gene products were available. Homolog-based predictions can
be used in order to enhance coverage of the genome. It is commonplace to assume that homo-
logs of druggable proteins will be druggable as well [3–7]. Yet, our analysis of a data set con-
taining crystal structures of homologous proteins for the NRDLD dataset does not support
such assumptions (Fig 1 and Table B in S1 File). Similar successful predictions were observed
for homologs with sequence identities ranging between 20–90%. However, when at least five
instances of homologous pockets were present with at least 80% consensus in druggability pre-
dictions, 100% correct predictions were obtained (Fig 1E). While the exact numbers will be
data set dependent, this provides guidelines on which criteria to apply when transferring struc-
ture-based druggability predictions between homologous proteins.
Full coverage of all perturbative P. aeruginosa proteins could not be achieved despite includ-
ing homolog-based druggability predictions (Table 2). The main reason is the lack of structural
data. While there are 992 perturbative proteins in the P. aeruginosa proteome, only 77 of them
have solved structures. This number increases to 642 when structures of homologs are also
considered. However, as more than one crystal structure of a homologous protein is needed to
obtain reliable predictions using DrugPred, this number is actually smaller. Another reason lies
in the difficulty of identifying pertinent pockets for computational analysis. DrugPred accepts
as input to mark a binding site also spheres generated by a pocket prediction program such as
FPOCKET [21,36]. However, for the current study we opted to only assess binding sites that
contained a ligand. This was done for the following two reasons. 1) Many groups have
attempted to devise new pocket prediction methods, however, unambiguous identification of
binding sites is not yet possible [37–48]. Consequently, including predicted pocked in a large
scale study is likely to introduce errors. 2) The apo-structure binding site conformation does
not necessarily represent the bound conformation [49,50]. This makes such pockets less useful
for predictions. Even so restricting the input structures to holo-structures further limited the
number of proteins we could address we believe that the obtained predictions are more mean-
ingful. It is evident from this discussion that there is a clear need for more structural data to
enable better coverage, especially in the presence of ligands. Previous endeavours have been
highly successful in this regard and must continue in the future [51].
Druggable proteins were identified by DrugPred 2.0 using crystal structures from P. aerugi-
nosa proteins itself, or else through its homologs (Table 3 and Table 4). It must be noted that
proteins are not necessarily less-druggable per se just because a pocket with druggable score
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was not observed. It’s possible that the crystal structure of the relevant domain or containing a
pocket with the required binding site conformation has not yet been crystallized. We therefore
consider the druggability status of these proteins as unknown, rather than less-druggable.
Some of the predicted druggable proteins like LpxC and DHFR are well known drug targets for
antibiotics while others like RmlA and PPAT were only recently pursued and drug-like inhibi-
tors were identified [29,30]. These findings validate our predictions and add confidence that
the predictions reported here are reliable. Other proteins were also found to possess druggable
binding pockets but have not yet been investigated using small molecules. For 15 out of the 29
druggable proteins, no inhibitors were submitted in ChEMBL to allow a chemogenomics-
based ranking. These proteins form promising novel targets for drug discovery against P.
aeruginosa.
The druggability predictions based on chemogenomics-based scoring and made by
DrugPred complemented each other. Predictions for 385 perturbative proteins are obtained
by combining both methods. The overlap between the methods was rather small with only 38
gene products. The reasons for this are either the lack of crystal structures suitable for drugg-
ability predictions (resulting in ranking by only the chemogenomics-based scoring system)
or no precedence of drug-like ligands (resulting in predictions only by DrugPred). This
clearly demonstrates that a larger coverage can be reached when complementary methods
are used. The chemogenomics-based method provides a rank-ordered list but does not pro-
vide a direct classification of druggable or less-druggable. Therefore, a direct comparison
between both methods is difficult. Still, when looking at the predicted druggable proteins for
which crystal structures from P. aeruginosa were available, a good agreement was observed
(Table 3). Low chemogenomics-based ranks for predicted druggable proteins were also
observed (Table 4) and can have several reasons: it is possible that the compounds used to
derive the chemogenomics-based score target a different binding site than those used for the
structure-based predictions. It might also be that the structures used for scoring do not con-
tain the binding site in a conformation relevant for binding a drug-like ligand. Further, there
is also possible that drug-like ligands have not yet been described or were not present in the
ChEMBL database. Finally, both computational methods have got short-comings and any
predictions obtained should always be viewed critically. Nevertheless, assessment by two
such independent methods provides confidence in those targets found to be druggable by
both and tremendously extends the coverage of the genome. Together, these tools can direct
drug discovery efforts.
Conclusions
The DrugPred methodology was redevised for high-throughput operation, involving the intro-
duction of new methods for calculation of descriptors. The old and new versions of DrugPred
showed similar accuracy, precision and recall parameters. Thus, DrugPred 2.0 is suitable for
large scale predictions.
A robust workflow and criteria to score homologous protein structures was established to
extend genome coverage. This procedure can readily be applied to other organisms for which
drug targets are sought.
This work was limited by the availability of solved structures, but with important advances
being made all the time in the field of structural biology, such bottlenecks may seize to exist in
the not-too-distant future. In the meantime, identification of 29 perturbative proteins of P. aer-
uginosa that may contain druggable pockets, including some of them with no or no drug-like
inhibitors deposited in ChEMBL, is a remarkable achievement that might drive drug discovery
efforts in the right direction.
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Methods
Construction of DrugPred 2.0
For speed and scale-up reasons, minor changes were introduced to the previous DrugPred ver-
sion. In particular, Openeye’s OEChem TK (OEChem, version 1.7.4, OpenEye Scientific Soft-
ware, Inc., Santa Fe, NM, USA) and Spicoli TK (Spicoli, version 1.1.2, OpenEye Scientific
Software, Inc., Santa Fe, NM, USA) were used to calculate the relative polar surface area
(psa_r), total hydrophobic surface area (hsa_t) and total contact surface area (csa), instead of
using Sybyl-X (Tripos, St. Louis, Missouri, USA) as done previously. [26,27] For that purpose,
any atoms whose solvent accessibility changed in the presence of the superligand were identi-
fied, and classified as polar and hydrophobic, respectively. Their solvent accessible surface in
the unbound state (SASAi) was then determined and used to calculate the relevant descriptors
using the following formulae:
csa ¼
XN
i¼1
ðSASAiÞ
hsat ¼
XN
i¼1
If atom is apolar; ðSASAiÞ
else; 0
(
psar ¼
csa hsat
csa
For building and validating a Partial Least Squares-Discriminant Analysis (PLS-DA) model,
the NRDLD dataset was modified as suggested previously and detailed in the result section
[21]. The new dataset of 110 structures was thus formulated accordingly. This modified dataset
was divided into a training set of 75 structures and a validation set of 35 structures. Descriptors
were calculated for the training set and a Partial Least Squares-Discriminant Analysis
(PLS-DA) model was built as done previously [21]. The new model was called DrugPred 2.0.
An ambiguous zone for uncertain predictions had previously been defined mathematically
using a one-sided 90% cut-off for both categories; 1.28 times the standard deviation of scores
for the less druggable structures was added to their mean score. Likewise, the same was sub-
tracted from the mean score for all druggable structures. This exercise generated a region of
statistical uncertainty, aptly named the ambiguous zone. DrugPred performed reasonably well
outside this zone of uncertainty, but a drop in performance was observed when data points
within the ambiguous zone were included. Accordingly, we attempted to establish the ambigu-
ous zone during the construction of DrugPred 2.0 as well. Using the same definition, we found
the ambiguous zone to be unreasonably small; suggesting this method for setting boundaries
for the ambiguous zone could no longer be used. However, it is reasonable to expect a region of
uncertainty with such models, so we arbitrarily built an ambiguous zone with the magnitude of
two score units, from 0.4–0.6, which is the middle of the scale and of similar size than the
ambiguous zone established with DrugPred 1.0.
Accuracy, precision and recall values were calculated as before [21]. Statistical analysis,
including DModX value determination, was carried out in the SIMCA-P+ package (www.
umetrics.com/products/simca).
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Preparation of structures for druggability analysis
Ligands were identified in each PDB file and unless a particular ligand was part of the list of
cofactors or common additives during the crystallography process (Table C in S1 File), it
was treated as a marker for its binding site. Any protein chains, cofactors and metals pre-
senting at least one atom within 3 Å of the ligand were retained as components of the bind-
ing site, while the rest were deleted. These reduced PDB files were processed using
DrugPred.
Identification of homologous structures of the NRDLD dataset
The NRDLD dataset, along with ligands marking the binding sites has been reported previously
[21] and was modified as described above. The ligand marking the binding site for each dataset
structure was identified and the surrounding chain that forms maximum contacts with it was
determined. Homologous structures for this chain were identified by sequence abstraction and
BLAST searches using a database containing all sequences for structures reported in the RCSB
PDB using an E-value cut-off of 1e-5. They were downloaded, followed by structure prepara-
tion as detailed above. These structures of homologous proteins were then subjected to struc-
tural alignment using PyMOL (The PyMOL Molecular Graphics System, Version 1.2r3pre,
Schrödinger, LLC.) and the Openeye OEChem toolkit was used to confirm vicinity of ligands
in the homologous chain, confirming that only pockets that are analogous to the one reported
in the modified NRDLD dataset were included.
The binding site identity between the parent pocket and the homologous pockets was calcu-
lated as follows: 1) A consensus pocket was generated. The consensus pocket consisted of all
residues that were either part of the parent pocket or the pocket found in the homolog. For that
purpose, the same pocket definition as for the descriptor calculation was used (e.g. change of
solvent accessibility in the presence of the superligand). 2) The sequences of the parent protein
and the homolog were aligned using ClustalW.[52] 3) For each residue in the consensus pocket
it was noted if a sequence match in the alignment was found. The sequence identity of the two
binding sites was then calculated as 100(number of sequence matches)/(number of binding
site residues) whereas residues that occurred at the same position in the alignment were only
counted once.
Percent consensus between different homologous pockets for the same NRDLD dataset
pocket was calculated using the formula: (100|#druggable—#less-druggable|)/(total number
of predictions). This measure enabled us to identify how many homologous pockets gave us
the same prediction regardless of the prediction itself.
Identification of crystal structures for P. aeruginosa proteins and their
homologs
The AEROPATH database (aeropath.lifesci.dundee.ac.uk, current release from 2010) contains
lists of crystal structures for P. aeruginosa proteins and their homologs. These structures were
downloaded from the in-house RCSB PDB mirror and subjected to structure preparation as
detailed above. Only those structures were retained where at least one ligand was obtained.
Repeated occurrences of the same ligand within the same PDB chain were not retained as it is
rare that the same ligand occupies different pockets in the same protein structure. An exception
to this rule was RmlA, where prior knowledge about a second pocket binding the cocrystallized
ligand was available; hence, a separate analysis was conducted in order to include both, the
active site and the allosteric pocket.
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Druggability predictions for gene products for which only crystal
structure from homologous proteins were available
For each parent gene product it was ensured that the binding sites of the crystal structures of
the homologous proteins covered the same sequence segment (Fig 2B). For final assessment,
only corresponding pockets represented in at least five different crystal structures were
retained. A protein pocket was considered to be druggable, if at least 80% consensus was
reached among the homologs and the majority of the pockets were predicted druggable. For
this purpose, percent consensus between different homologous pockets belonging to the same
parent entry was calculated using the formula: (100|#druggable—#less-druggable|)/(total
number of predictions).
Supporting Information
S1 File. Modified NRDLD set together with descriptor values and predictions (Table A).
Results from homolog-based druggability predictions for the NRDLD dataset structures when
using an ambiguous zone (Table B). List of PDB 3-letter codes for cofactors or common additives
during the crystallography process. These compounds were not considered to mark a binding
pocket (Table C). Scripts are available on https://github.com/ruthbrenk/DrugPred2.0.git.
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